Spinal cord compression: recognising MSCC and the GP emergency response

Spinal cord compression is a neurological emergency where the window for preserving function is measured in hours. The most important thing a GP can do is recognise it early — before paralysis is established — give IV dexamethasone 16 mg, and arrange Cat-1 transfer. Metastatic spinal cord compression (MSCC) affects approximately 5–10% of all cancer patients at some stage; lung, breast, and prostate cancer together account for roughly half of all cases. In approximately 20% of MSCC presentations, the cord compression is the index event that leads to the cancer diagnosis. Ambulatory status before treatment is the single strongest predictor of post-treatment function.

A. Core clinical — the AU general-practice framework

The red flag triad

Any combination of the following in a patient with known or suspected malignancy is MSCC until proven otherwise:

1. Progressive back pain — new, severe, nocturnal, focal at a vertebral level, or worsening over days to weeks in a cancer patient.
2. Bilateral lower limb weakness — progressive difficulty climbing stairs, rising from a chair, or unsteady gait.
3. Bladder or bowel dysfunction — urinary urgency, hesitancy, retention, overflow incontinence, or new constipation / faecal incontinence.

A sensory level on the trunk (band of numbness below the level of compression) or saddle anaesthesia (lumbar / cauda equina) strengthens the diagnosis. Do not wait for paralysis — once paralysis is established, the likelihood of functional recovery falls substantially.

NICE CG75 recommends same-day MRI of the whole spine for any patient with cancer who develops new spinal pain plus any new neurological symptom. eTG complete — Spinal cord syndromes supports immediate dexamethasone and Cat-1 transfer on clinical suspicion, before imaging is confirmed.

Causes of spinal cord compression

Cause	Notes
Metastatic (extra-dural) ~85%	Vertebral collapse + epidural soft tissue extension; lung, breast, prostate most common
Epidural abscess	S. aureus or MRSA; IVDU, immunocompromise, indwelling devices, recent spinal procedure; fever + raised ESR/CRP
Pott disease (spinal TB)	Migrants from endemic regions; chronic course; paraspinal cold abscess; AFB on culture
Traumatic vertebral fracture	High-energy; also low-energy in osteoporotic elderly
Central disc herniation	Younger patients; rapid-onset bilateral leg weakness; usually thoracic or cervical
Spinal haematoma	Anticoagulant therapy; post-procedural; sudden onset
Primary spinal tumour	Ependymoma, astrocytoma, meningioma, schwannoma — uncommon

Focused history

Back pain characteristics:

• New onset in a patient with any cancer history.
• Progressive over days to weeks.
• Nocturnal — wakes the patient from sleep (distinguishes metastatic from mechanical).
• Focal at one vertebral level (vs diffuse osteoarthritic pain).
• Severe and escalating; worse with movement, Valsalva, or coughing.

Neurological symptoms:

• Bilateral lower limb weakness (difficulty climbing stairs, standing from seated).
• Sensory level — band of numbness or tingling at a specific trunk level.
• Bladder symptoms — urgency, hesitancy, retention, incontinence.
• Bowel symptoms — constipation, reduced sensation, incontinence.
• Sexual dysfunction.
• Walking unsteadiness or falls.

Past medical:

• Known malignancy — type, stage, current systemic treatment, most recent imaging.
• Constitutional cancer “B” symptoms — unintentional weight loss, night sweats, fatigue.
• Risk factors for infection — IV drug use, recent spinal procedure, immunocompromise, indwelling devices, dental work, TB exposure or endemic country travel.
• Anticoagulant therapy (haematoma risk).
• Recent trauma — even minor falls in an osteoporotic patient.

Examination

• Vital signs — fever and tachycardia suggest infective aetiology; hypotension in traumatic.
• Spine: focal tenderness at the affected vertebral level; step deformity (vertebral collapse); paraspinal muscle spasm; erythema or warmth (infection).
• Neurological (comprehensive):
  • Motor — power, tone, coordination, gait.
  • Upper motor neurone signs below the level — pyramidal weakness pattern, increased tone, clonus, hyperreflexia, upgoing plantars (Babinski positive).
  • Spinal shock (early, hours to days) — flaccid, areflexic; evolves to spasticity over days.
  • Sensory — document the level precisely (T4 = nipple line; T6 = xiphisternum; T10 = umbilicus; T12 = inguinal ligament).
  • Perianal sensation, anal tone, bulbocavernosus reflex.
• Bladder — palpate and/or bladder scan; catheterise for urinary retention.
• Systemic — lymphadenopathy, breast examination, rectal examination (prostate), thyroid, abdominal masses — signs of the primary malignancy.

Investigations

• Bloods: FBC + film (cytopenias with marrow infiltration; leucocytosis in infection); UEC + calcium (hypercalcaemia of malignancy); LFTs + ALP (raised in metastatic bone disease); PSA (men); SPEP / IFE / FLC (myeloma); ESR + CRP (markedly elevated in infection); coagulation screen (anticoagulant haematoma); blood cultures (if infective).
• Imaging — URGENT:
  • MRI whole spine with gadolinium (MBS items 63179 / 63183) — gold standard; identifies level, cord signal change, cause, and extent of compression. Requested urgently under specialist via ED; does not delay initial treatment.
  • CT myelogram — if MRI is contraindicated (pre-2016 cardiac pacemaker, severe claustrophobia).
  • Plain X-ray — limited sensitivity; can show vertebral collapse, lytic or sclerotic lesions, paraspinal soft-tissue mass.
  • CT chest / abdomen / pelvis (MBS 56401) — staging and search for primary malignancy if unknown.
  • PET-CT (MBS 61653) — selected oncology indications.
• Tissue sampling (hospital-led): CT-guided percutaneous biopsy of the vertebral lesion if primary unknown; bone marrow biopsy if myeloma or lymphoma suspected; abscess aspirate if infective.
• Bladder scan — to guide catheterisation decision.

GP emergency management before transfer

1. Give IV dexamethasone immediately — 16 mg loading dose (10 mg slow IV bolus followed by 6 mg IV over 5 minutes), or 16 mg orally if IV access is not yet established. Then 4 mg IV or orally every 6 hours. NICE CG75 recommends this immediately on clinical suspicion, before imaging, because the oedematous component of cord injury is partially reversible.
2. Strict bed rest and log rolling — no sitting up without coordinated log rolling until imaging confirms spinal stability. Mobilise only under specialist instruction.
3. Catheterise for urinary retention — palpate or bladder-scan the bladder before transfer.
4. Analgesia — paracetamol 1 g IV or PO; opioid as required (fentanyl 25–50 µg IV titrated); avoid NSAIDs in the context of cancer (renal, bleeding, bone metastasis concerns).
5. DVT prophylaxis — mechanical (TED stockings, pneumatic compression) as first-line in acute neurological deficit; pharmacological anticoagulation deferred to specialist decision (bleeding risk in unknown pathology).
6. Pre-notify the receiving ED and neurosurgical team — include cancer history, neurological findings, and timing of symptom onset.
7. Cat-1 transfer — call 000.

B. Evidence: surgery versus radiotherapy and the Patchell trial

Surgery plus radiotherapy: the landmark evidence

The pivotal randomised controlled trial by Patchell et al. (Lancet 2005) compared direct decompressive surgery followed by radiotherapy against radiotherapy alone in patients with MSCC and intact or recoverable neurological function. Surgery plus radiotherapy was superior on every meaningful outcome: more patients maintained ambulation (84% vs 57%), maintained continence (156 vs 85 median days), and survived longer (median 126 vs 100 days). The trial established surgery followed by radiotherapy as the standard of care for patients with:

• A single area of compression.
• Prognosis ≥3 months.
• Adequate performance status for surgery.

Patients with radiosensitive tumours (lymphoma, myeloma, germ cell) and no bone instability may achieve good results with radiotherapy alone as primary treatment.

Dexamethasone dosing

NICE CG75 recommends a loading dose of 16 mg dexamethasone immediately on clinical suspicion, followed by 4 mg every 6 hours, continuing until definitive treatment. Higher doses (96 mg) have been studied but not shown to improve outcomes and carry greater toxicity (psychiatric effects, hyperglycaemia, infection, avascular necrosis). Taper the dose after surgery or radiotherapy under specialist guidance — do not stop abruptly.

Stereotactic body radiotherapy (SBRT)

SBRT delivers a precisely focused, ablative dose of radiation with steep dose gradients that spare adjacent cord. It is increasingly used for radioresistant histologies (renal cell carcinoma, melanoma, hepatocellular carcinoma), post-conventional radiotherapy recurrence, and in combination with surgery. Access in Australia is limited to major radiation oncology centres. Decision on SBRT versus conventional radiotherapy is made by the treating radiation oncologist and MDT.

Bone-modifying agents

For patients with metastatic bone disease — particularly breast cancer, prostate cancer, and multiple myeloma — zoledronic acid (PBS Authority Required) and denosumab (Xgeva; PBS Authority Required) reduce skeletal-related events (SREs), including pathological fracture and spinal cord compression. ASCO 2024 bone-modifying agents guideline supports their continued use in patients receiving systemic therapy for bone metastases. Monitor for osteonecrosis of the jaw (ONJ) and atypical fractures with long-term use; dental review before commencing.

C. Hospital management and rehabilitation

Definitive treatment in the neurosurgical centre

Malignant SCC:

• Surgery — decompression and stabilisation within 24–48 hours for eligible patients (single level, prognosis ≥3 months, adequate performance status, solid tumour). Approaches include posterior laminectomy plus fixation, corpectomy, or TLIF depending on the level and anatomy.
• Conventional palliative radiotherapy — for patients ineligible for surgery; multiple fractions.
• SBRT — for radioresistant histologies or recurrence after conventional radiotherapy; specialist-led.
• Systemic therapy — chemotherapy, hormonal therapy, immunotherapy, targeted agents per primary malignancy.
• Bisphosphonate / denosumab — started or continued per oncology MDT.

Infective SCC:

• Urgent surgical drainage and decompression.
• Empiric antibiotics post-culture: vancomycin + ceftriaxone + metronidazole per eTG; refined by culture and sensitivity. Six to eight weeks of IV antibiotics is typical for spinal osteomyelitis.

Traumatic SCC:

• Stabilisation per orthopaedic / neurosurgical + ATLS pathway. Methylprednisolone for acute traumatic spinal cord injury is not recommended by current AANS guidelines — earlier NASCIS trial benefit has not been confirmed on re-analysis.

Rehabilitation and survivorship

Multidisciplinary spinal rehabilitation includes:

• Physiotherapy — mobility, transfer training, strengthening, spasticity management.
• Occupational therapy — assistive devices, home modification, activities of daily living.
• Bladder management — intermittent self-catheterisation (preferred in selected patients), indwelling or suprapubic catheter, continence nurse support.
• Bowel programme — regular toileting, aperients, digital stimulation, manual evacuation as needed.
• Pressure injury prevention — repositioning protocols, pressure-relieving mattress.
• DVT prophylaxis — ongoing mechanical and, once haemostasis confirmed, pharmacological.
• Sexual rehabilitation — referral to specialist service.
• Mental health support — GP-initiated MHCP (MBS items 2715 / 2717); psychology or psychiatry for adjustment disorder, grief, and depression.
• Dietitian — nutritional optimisation for recovery and bone health.
• NDIS application — for patients under 65 years with persistent SCC-related disability; initiate early as the application process takes time.
• Vocational rehabilitation — where return to work is a goal.

D. Australian operations

MBS items for GP-led care

Item	Descriptor
23 / 36 / 44	Level B / C / D consultation
965 / 967	GP Chronic Condition Management Plan (post-SCC survivorship coordination)
2715 / 2717	Mental Health Treatment Plan (adjustment disorder, depression, chronic pain)
715	ATSI annual health assessment
91890 / 91891	Telehealth consultation (post-discharge monitoring, stable survivorship)
63179 / 63183	MRI whole spine with gadolinium (requested under specialist via ED)
56401	CT chest / abdomen / pelvis (staging, search for primary)
61653 / 61678	PET-CT (selected oncology indications)

PBS items relevant to MSCC management

• Dexamethasone — PBS General Schedule (multiple indications).
• Zoledronic acid (Aclasta) — Authority Required for metastatic bone disease in breast cancer, prostate cancer, and myeloma.
• Denosumab (Xgeva) — Authority Required for bone metastases.
• Opioid analgesia — General + Authority depending on formulation; SafeScript / RTPM monitoring applies.
• Anti-cancer therapy per primary malignancy — PBS Authority varies by indication.
• Antibiotics for spinal infection — PBS General or Authority depending on agent.

Referral pathway

Scenario	Referral	Urgency
Suspected MSCC (back pain + neurology in cancer)	000 → neurosurgical centre via ED	Cat-1 immediate
Any new neurological signs in cancer patient	000 + pre-notify ED + neurosurgery + radiology	Cat-1
Suspected spinal epidural abscess	000 + ED + neurosurgery + infectious diseases	Cat-1
Stable post-treatment MSCC — GP review	GP + physiotherapy + continence nurse	Within 1 week of discharge
Progressive functional decline in known MSCC	Oncology / neurosurgery	Semi-urgent
Bone metastases without cord signs — monitoring	Oncology + GP shared care	Per oncology protocol

Guideline alignment

AU: Cancer Australia OCP · Cancer Council Australia · eTG complete — Spinal cord syndromes · RACS.

International: NICE CG75 — Metastatic spinal cord compression · ASCO 2024 — Bone-modifying agents.

E. Special populations

Aboriginal and Torres Strait Islander peoples

Remote and very remote communities face extended transport times to neurosurgical centres — neurological deterioration during transfer time may be irreversible. A low threshold for early aeromedical retrieval (Royal Flying Doctor Service) is essential. Spinal TB (Pott disease) occurs more frequently in communities with TB exposure, recent migration history, or crowded living conditions; consider mycobacterial infection in any chronic back pain with cord signs in this context. Coordinate with ACCHO and tertiary centre. Closing the Gap PBS co-payment applies to post-operative medications including bone-modifying agents.

Late-presenting cancer

In approximately 20% of MSCC cases, the cord compression is the presenting event leading to cancer diagnosis. The GP who suspects MSCC initiates the full diagnostic cascade: MRI whole spine, CT chest / abdomen / pelvis staging, tissue biopsy if required, and urgent oncology referral — all coordinated from the hospital setting. The primary malignancy often becomes apparent within days of acute management.

Multiple myeloma

Myeloma causes vertebral destruction and cord compression through multiple mechanisms — lytic lesions, vertebral collapse, and extramedullary plasmacytoma. Myeloma is among the most radiosensitive of malignancies; patients often respond well to radiotherapy alone without surgery, depending on bone stability. SPEP / IFE / FLC testing is essential in any unexplained vertebral fracture or back pain in a patient aged over 50. Bone-modifying agents are standard of care.

Patients with pre-existing neurological disease

Patients with multiple sclerosis, motor neurone disease, or prior spinal surgery who develop worsening neurological symptoms require careful assessment to distinguish disease progression from a new compressive event. MRI is essential; clinical pattern alone is insufficient. Involve the treating neurologist or neurosurgeon early.

Palliative and end-of-life context

For patients with very advanced malignancy, short prognosis (under 3 months), or multiple levels of compression, surgical intervention may not be appropriate. Palliative radiotherapy remains an option for pain control and limited neurological preservation. Goals-of-care discussion — covering preferences regarding surgery, radiotherapy, catheterisation, hospitalisation, and resuscitation status — is best established proactively rather than during an acute deterioration. Advance care planning documents should be available at every hospital contact.

When to escalate

• Call 000 immediately for any patient with cancer and new back pain plus bilateral leg weakness, bladder or bowel dysfunction, or sensory level on the trunk — this is MSCC until proven otherwise.
• Give IV dexamethasone 16 mg before transfer — do not wait for scan confirmation.
• Same-day ED for any new neurological symptom in a cancer patient, even if cord compression is not yet confirmed.
• Senior GP or specialist telephone advice if uncertain about clinical urgency — a missed MSCC is a catastrophic outcome; err toward transfer.
• Oncology or palliative care early for patients with advanced disease and bone metastases, to anticipate and plan for the risk of future MSCC.

What this article is and is not

This article summarises current Australian and international guideline recommendations for the recognition and emergency management of spinal cord compression, written to support GP decision-making in the acute setting. It is not a substitute for clinical judgement, neurosurgical or oncological assessment, or the full NICE CG75 and Cancer Australia guideline text. Decisions about surgical approach, radiotherapy technique, SBRT, and systemic therapy are made by the treating multidisciplinary team.

This article does not constitute individual medical advice. Patients with back pain and any new neurological symptom — particularly those with a cancer history — should seek immediate GP assessment or, if symptoms are severe or rapidly worsening, call 000 or present to the nearest emergency department.

---

Sources cited

1. NICE CG75 — Metastatic spinal cord compression
2. Cancer Australia — Optimal Care Pathway for Spinal Cord Compression
3. Cancer Council Australia
4. eTG complete — Spinal cord syndromes
5. RACS — Royal Australasian College of Surgeons
6. ASCO 2024 guideline — Bone-modifying agents and metastatic spinal cord compression
7. Patchell RA et al. Direct decompressive surgical resection in the treatment of MSCC. Lancet 2005
8. Australian Medicines Handbook — dexamethasone dosing and interactions
9. MBS Online — items 23, 36, 44, 56401, 61653, 61678, 63179, 63183, 715, 965, 967, 2715, 2717, 91890, 91891
10. Pharmaceutical Benefits Scheme — dexamethasone, zoledronic acid (Authority), denosumab (Authority), opioids (General + Authority + SafeScript)
11. NDIS — National Disability Insurance Scheme
12. SpinalCure Australia